Survodutide
Also known as: BI 456906
Survodutide is a dual GLP-1 / glucagon receptor agonist co-developed by Boehringer Ingelheim and Zealand Pharma. NOT FDA-approved; received FDA Breakthrough Therapy Designation in 2024 for non-cirrhotic MASH with moderate/advanced fibrosis. Phase 3 ongoing (SYNCHRONIZE in obesity/T2DM; LIVERAGE and LIVERAGE-Cirrhosis in MASH).
0 listings, ranked by trust score
Each row is a (vendor, peptide) pair. Click through for the listing detail, the vendor's full trust profile, and any COAs they've published.
No vendors carrying this peptide are indexed yet.
COAs for Survodutide
11 third-party tests across 3 vendors. Each card links to the full report.
For
Survodutide
by Skye Peptides· batch SV25-12-001
For
Survodutide
by Skye Peptides· batch SV25-06-001
For
Survodutide
by Profound Aminos· batch 2025-01-23
For
Survodutide
by Hydro Research Peptides· batch 2024-08-05
For
Survodutide
by Hydro Research Peptides· batch Survodutide-6028
Purity not on file
For
Survodutide
by Skye Peptides· batch SV25-12-001
Purity not on file
For
Survodutide
by Skye Peptides· batch SV25-12-001
Purity not on file
For
Survodutide
by Skye Peptides· batch SV25-06-001
Purity not on file
For
Survodutide
by Skye Peptides· batch SV25-06-001
Purity not on file
For
Survodutide
by Hydro Research Peptides· batch Survodutide-6028
Purity not on file
For
Survodutide
by Hydro Research Peptides· batch Survodutide-6028